Sangamo Therapeutics Inc (NASDAQ:SGMO) gapped down prior to trading on Wednesday . The stock had previously closed at $17.79, but opened at $17.25. Sangamo Therapeutics shares last traded at $17.25, with a volume of 3233086 shares changing hands.
A number of equities research analysts have recently commented on the company. BidaskClub raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. ValuEngine raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research report on Friday, February 23rd. Wedbush reaffirmed a “hold” rating and issued a $8.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 13th. Finally, Piper Jaffray set a $25.00 price objective on Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Buy” and an average target price of $20.83.
The stock has a market cap of $1,567.05, a P/E ratio of -24.64 and a beta of 2.80. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.54 and a quick ratio of 5.54.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative return on equity of 31.44% and a negative net margin of 149.23%. The business had revenue of $13.08 million during the quarter, compared to the consensus estimate of $11.10 million. During the same quarter in the previous year, the business earned ($0.14) earnings per share. The business’s revenue for the quarter was up 46.6% on a year-over-year basis. analysts predict that Sangamo Therapeutics Inc will post -0.15 earnings per share for the current fiscal year.
In related news, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $308,850.00. Following the transaction, the vice president now owns 29,625 shares in the company, valued at $609,978.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Friday, April 6th. The shares were sold at an average price of $17.41, for a total value of $87,050.00. The disclosure for this sale can be found here. Insiders sold 103,059 shares of company stock worth $2,214,622 in the last quarter. 5.50% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of SGMO. Alexandria Capital LLC acquired a new position in Sangamo Therapeutics in the fourth quarter valued at $15,179,000. Tocqueville Asset Management L.P. lifted its stake in shares of Sangamo Therapeutics by 105.0% during the fourth quarter. Tocqueville Asset Management L.P. now owns 665,890 shares of the biopharmaceutical company’s stock worth $10,921,000 after purchasing an additional 341,075 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Sangamo Therapeutics by 58.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock worth $14,948,000 after purchasing an additional 336,107 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Sangamo Therapeutics by 908.6% during the fourth quarter. Two Sigma Advisers LP now owns 290,479 shares of the biopharmaceutical company’s stock worth $4,764,000 after purchasing an additional 261,679 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Sangamo Therapeutics by 1,403.7% during the fourth quarter. Two Sigma Investments LP now owns 194,719 shares of the biopharmaceutical company’s stock worth $3,193,000 after purchasing an additional 181,770 shares in the last quarter. Hedge funds and other institutional investors own 65.16% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/25/sangamo-therapeutics-sgmo-shares-gap-down-to-17-25.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.